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Abstract
Background: Bladder small cell carcinoma is an uncommon tumour. Through a retrospective
study we will present the evolution of recurrent and metastatic disease and outcome of patients
treated at Léon-Bérard Cancer Centre.
Methods: Only 15 patients having recurrent or metastatic bladder small cell carcinoma were
treated at Léon-Bérard Cancer Centre between 1996 and 2007. The patients were divided in two
groups: a mixed small cell carcinoma group (9 patients) and a pure small cell carcinoma group (6
patients). All the records and informations related to treatment and outcome of the 15 patients
were retrospectively analyzed. Various characteristics of small cell carcinoma were investigated.
Results: The median age of the 15 patients having recurrent or metastatic bladder small cell
carcinoma and treated at Léon-Bérard Cancer Centre was 63 years and the disease was at stage
IV for all cases. Nine patients were treated by chemotherapy. Four patients were treated by local
radiotherapy (3 with radiotherapy without previous surgery and 1 with surgery followed by
radiotherapy) and chemotherapy. One patient was treated by whole brain radiotherapy. And one
patient died before treatment. After 52.4 months median follow up, 12 patients died. Median
overall survival was 7.6 months. Survival probability at 1 year was 33%. Median overall survival was
9.9 months in the mixed small cell carcinoma group, and was only 4.6 months in the pure small cell
carcinoma group. Survival probability at 1 year in the mixed small cell carcinoma group was 44% as
compared to 17% in the pure small cell carcinoma group (Log-rank test: p = 0.228).
Conclusion: Recurrent and metastatic bladder small cell carcinoma is associated with very poor
prognosis. The pure bladder small cell carcinoma appears to have poorer outcome than the mixed
bladder small cell carcinoma. Chemotherapy using platinum drugs is a mainstay treatment.
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Background
Whereas small cell cancer is a common histological vari-
ant accounting for 14% of all primitive cancers arising
from the lung [1], small cell carcinoma of the bladder
(SCCB) is extremely rare and accounts for less than 1% of
all cancers arising from the bladder [2,3]. To our knowl-
edge, 882 cases have been reported in the literature as
extra-pulmonary localizations of small cell carcinomas.
The first case was described in 1981 by Cramer et al [4].
Small cell carcinoma (SCC) is often, but not always neu-
roendocrine tumour. The diagnosis of SCCB is based on
criteria established by the WHO classification system.
Those criteria are identical to those used to diagnose small
cell lung cancer (SCLC) [5]. Immunochemical staining
can be extremely helpful in establishing the diagnosis.
This tumour is associated with a more aggressive behav-
iour and poorer prognosis than transitional cell bladder
carcinoma (TCC), and is mostly diagnosed at advanced
stages. Because of the rarity of the disease, no standard
treatment had yet been proposed. Treatment algorithms
have been extrapolated from the treatment of small cell
cancer arising in the lung and often involved chemother-
apy regimens using a platinum agent. We conducted a ret-
rospective analysis of all cases of recurrent or metastatic
small cell carcinoma of the bladder treated at the Léon-
Bérard Cancer Centre over a 12-year period for definition
of patient's outcome.
Methods
All the files of patients with locally advanced or metastatic
carcinoma of the bladder that were treated at the Léon-
Bérard Cancer Centre between January 1996 and Decem-
ber 2007, were retrospectively reviewed to select all the
cases with metastatic or recurrent small cell disease.
Patients were considered to have small cell carcinoma of
the bladder if pathological examination of their tumour
revealed the presence of any small cell component accord-
ing to the WHO classification [5]. We considered and ana-
lysed each patient medical records for further
investigations of demographics, clinical stage, histological
results, treatments and outcome. Radiological reports
were reviewed to determine the stage of the disease caused
by recurrent or metastatic small cell carcinoma of the
bladder, at the time of diagnosis, using the 2002 TNM
classification for genitourinary tumours. Data about the
different treatments used: surgery, chemotherapy and
radiotherapy were extracted from each patient medical
record. The date and site of recurrence and, if applicable,
the date and cause of death were also considered. Survival
was analyzed statistically in all patients. Overall survival
was calculated from the date of diagnosis of recurrent or
metastatic disease to the date of death or to the date of last
follow up. We retrospectively compared survival between
pure small cell carcinoma group (n = 6) and mixed small
cell carcinoma group (n = 9), despite of the fact that the
two groups of patients were too small and biased by a vari-
ety of different therapies. The Kaplan-Meier method was
used to calculate median overall survival. The log-rank test
was used to evaluate the differences between the two
groups. Approval for the study was obtained from Léon-
Bérard Cancer Centre, Lyon, France; Date 16/Jul/2007.
Results
Between 1996 and 2007, 911 patients with locally
advanced or metastatic bladder cancer were treated at the
Léon-Bérard Cancer Centre. Only seventeen patients had
small cell histology of which 15 had recurrent or meta-
static disease. Twelve of the cases analysed in the present
study were also included in the study of localized disease
and have been the subject of one previous published
report [6]. Median age at diagnosis of metastatic or recur-
rent SCCB was 63 years (range: 45 to 78 years). Fourteen
patients were male and one was female. Sixty percent of
the patients were smokers. For patients with recurrent dis-
ease the pathological diagnosis of SCCB was previously
performed before the initial management of the limited
stage disease, by cystoscopy and transurethral resection of
the bladder tumour (TURBT). For patients with metastatic
disease at the time of first presentation, the pathological
diagnosis was also performed by cystoscopy and TURBT.
Nine patients had both transitional cell and small cell his-
tology (60%), while 6 had exclusively small cell histology
(40%). All 15 patients had stage IV disease according to
the 2002 TNM classification for genitourinary tumours.
Two had limited stage disease and 13 had extensive stage
disease in analogy to the two staging system adopted for
staging SCLC. Table 1 summarizes the characteristics and
clinico-pathological records of patients. Twelve patients
were recurrent or metastatic after prior management of the
localised stage disease [6]. Eleven of whom were previ-
ously treated by radical cystectomy and one by chemo-
Table 1: Demographic and histopathological characteristics (n = 15).
Characteristics
Age at diagnosis
Median 63 years
Range 45 – 78 years
Gender
Male 14
Female 1
Smoking history
Present 9 (60%)
Absent 6 (40%)
Histologic finding
SmCC only 6 (40%)
SmCC and TCC 9 (60%)
Stage
Stage IV(M0) 2
Stage IV(M+) 13
SmCC = small cell carcinoma; TCC = transitional cell carcinomaBMC Urology 2009, 9:4 http://www.biomedcentral.com/1471-2490/9/4
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therapy alone because he refused the surgical resection
[6]. From theses 12 patients, 2 had local recurrence (one
in the neo-bladder and the second in the rectum), 3 had
retroperitoneal metastasis, 2 had central nervous system
(CNS) metastasis, 2 had liver and retroperitoneal (RP)
metastasis, 1 had liver and bone metastasis, 1 had lung
and retroperitoneal metastasis and 1 had lung metastasis.
Three patients were metastatic at diagnosis: 1 had liver,
lung and mediastinum metastasis, 1 had lung and bone
metastasis and 1 had bone metastasis. Nine patients were
treated by chemotherapy. Three patients were treated by
chemotherapy and radiotherapy (sequential treatment).
One patient, with rectal recurrence, was treated by surgery,
chemotherapy and radiotherapy. One patient, with CNS
metastasis, was treated by whole brain radiotherapy. And
one patient died before treatment. Tables 2 and 3 summa-
rize the treatments used and the outcome of all patients.
Table 4 summarizes chemotherapeutic regimen used to
treat patients in the present study. The RECIST criteria
were used to determine the response to the treatments
mentioned in table 2 and 3. After 52.4-month median fol-
low up, 11 patients died with SCCB and 1 died with sep-
sis. Median overall survival was 7.6 months. Survival
probability at 1 year was 33% (figure 1). Median overall
survival was 9.9 months in the mixed small cell carcinoma
group, as compared with 4.6 months in the pure small cell
carcinoma group. Survival probability at 1 year in the
mixed small cell carcinoma was 44% as compared to 17%
in the pure small cell carcinoma group (Log-rank test: p =
0.228) (figure 2). Mean survival was 14.7 months for
patients (n = 9) treated by chemotherapy and 13.8
months for patients (n = 4) treated by chemotherapy and
local radiotherapy treatments (3 with radiotherapy and 1
with surgery followed by radiotherapy).
Discussion
Primary SCCB is a rare disease that accounts for less than
1% of all bladder cancers [2,3]. The relatively high inci-
Table 3: Table showing localisation of metastasis, pathologic and treatment characteristics and outcome of patients with metastatic 
disease at presentation.
Localisation of metastasis Histology 
(Mixed or pure SmCC)
Treatment Response Survival (months) Death
Liver and Lung and 
Mediastinum
Mixed CT (22EP) PR > 70% 51.8 no
Lung and bone Pure CT (4EP) + RT (Y 45 Gy) + RT in 
the bladder (24 Gy).
PR < 50% 11.7 yes
Bone Pure none NA 1 yes
SmCC = small cell carcinoma; CNS = central nervous system; RP = retroperitoneal; EP = etoposide and cisplatin; G = gemcitabine; GC = 
gemcitabine plus cisplatin; MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; MTX = methotrexate; CT = chemotherapy; RT = 
radiotherapy; Y = Y field radiotherapy; PR = partial response; NA = not applicable
Table 2: Table showing localisation of recurrence, pathologic and treatment characteristics and outcome of patients with local and 
metastatic recurrence
Localisation of 
recurrence
Histology 
(Mixed or pure SmCC)
Treatment Response Survival (months) Death
Rectum mixed Surgery + CT (3EP) + RT Progressive 7.1 yes
Neo-bladder Mixed CT (6MVAC) PR < 50% 10 yes
RP Pure CT (4EP) Stable 5.5 yes
RP Mixed RT (Y 45 Gy) + 
chemotherapy (4G)
Stable 7.7 yes
RP Mixed CT (4GC) + RT (Y 45 Gy) CR 28.8 yes
CNS Pure CT 
(1 EP + 1 MTX intrathecal)
- 0.4 yes
CNS Pure RT (30 Gy) Progressive 3.7 yes
Liver and RP Mixed CT (1GC) Progressive 0.7 yes
Liver and RP Mixed CT (4G) Progressive 3.1 yes
Liver and Bone Pure CT (6EP) PR > 50% 20.3 no
Lung and RP Mixed CT (6EP) PR > 50% 14.7 no
Lung Mixed CT 
(6EP in first line and 6GC in 
second line)
PR > 50% (in first line) 26.3 yes
SmCC = small cell carcinoma; CNS = central nervous system; RP = retroperitoneal; EP = etoposide and cisplatin; G = gemcitabine; GC = 
gemcitabine plus cisplatin; MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; MTX = methotrexate; CT = chemotherapy; RT = 
radiotherapy; Y = Y field radiotherapy; PR = partial response; CR = complete response, NA = not applicableBMC Urology 2009, 9:4 http://www.biomedcentral.com/1471-2490/9/4
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dence of 1.8% reported here might reflect a bias due to the
fact that our centre mostly recruits patients with meta-
static bladder cancer. Primary SCCB was initially
described in 1981 by Cramer et al [4]. Since then, 882
cases of SCCB have been published up to January 2009.
Pathogenesis was uncertain; however the multipotent
stem cell theory applies best to this case [7-9].
When considering histological tests, SCCB is indistin-
guishable from its pulmonary counterpart. The diagnosis
is accomplished via cystoscopy and histological analysis
of the transurethral resection of bladder tumour. The diag-
noses were based on the criteria established by the WHO
classification system, and were identical to those related
to the diagnosis of SCLC [5]. Microscopically, the tumour
was composed of sheets of uniformly small, round mitot-
ically active cells with overlapping nuclei and evenly dis-
tributed chromatin, lacking prominent nucleoli. Nuclear
moulding, tumour necrosis and crush artefact were com-
monly seen [10]. Immunohistochemical staining and
Overall survival of patients with recurrent or metastatic small cell carcinoma of the bladder (OS): The median duration of  overall survival was 7.6 months [n = 15, 12 events (deaths)] Figure 1
Overall survival of patients with recurrent or metastatic small cell carcinoma of the bladder (OS): The median 
duration of overall survival was 7.6 months [n = 15, 12 events (deaths)]. Survival probability at 1 year was 33%.
Table 4: Table summarizes chemotherapeutic regimen used to treat patients in the present study.
Regimen Schedule Drugs and doses
EP On day 1 to 3, repeated after 
21 days
Etoposide
120 mg/m2 on day 1 to 3
Cisplatin
80 mg/m2, on day 1
MVAC On day 1, 2, 15, and 22, 
repeated after 28 days
Methotrexate
30 mg/m2 on day 1, 15 and 
22
Vimblastine
3 mg/m2 on day 2, 15, and 22
Doxorubicin
30 mg/m2 on day 2
Cispatin
70 mg/m2 on day 2
GC On day 1, 2, 8, and 15, 
repeated every 28 days
Gemcitabine
1000 mg/m2 on day 1, 8 and 
15
Cisplatin
70 mg/m2, on day 2
G On day 1, 8 and 15 repeated 
after 21 days
Gemcitabine
1000 mg/m2
EP = etoposide and cisplatin; MVAC = methotrexate, vimblastine, doxorubicin and cisplatin; GC = gemcitabine and cisplatin; G = gemcitabineBMC Urology 2009, 9:4 http://www.biomedcentral.com/1471-2490/9/4
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analysis showed that the cells expressed the effect of: 1-
the markers of neuroendocrine differentiation, including
synaptophysin (expressed at a rate of 66.6 to 76%), neu-
ron-specific enolase (25 to 100%), and chromogranin (22
to 89%); 2- the epithelial markers: EMA (77.7%),
Cytokeratine7 (59%), and CAM 5.2. 3 (47 to 66.6%); 3-
other markers were less commonly expressed: TTF1 (39 to
50%), C-KIT (22 to 27%) and EGFR (27 to 36%) [3,10-
16]. In the present study, we found that most small cell
bladder cancers (60%) were mixed with transitional cell
carcinoma. In concordance with our results, the mean per-
centage of mixed SCCB obtained by the analysis of the
most important published series was equal to 56%
[2,3,6,10,17-22]. Other teams have shown a higher inci-
dence of pure small cell carcinoma [3,18,19,21].
Small cell bladder cancer was highly aggressive as most of
the patients (up to 95%) were diagnosed at advanced
stage (Stage II or more), from whom 25% were metastatic
and two-thirds developed distant recurrence [18,20,23].
Theses finding suggest that the current TNM staging sys-
tem used for bladder TCC may not be appropriate for
SCCB, leading the scientific community to recommend
the use of the two staging system (actually in practice):
limited and extensive stages in analogy to SCLC
[17,21,22,24,25].
Because small cell carcinoma of the bladder was rare, and
due to lack of randomized controlled trials, no standard
treatment of this disease was proposed. However, chemo-
therapy played a prominent role in the management of
these tumours. The prognostic of SCCB was poor even in
limited stage disease [20]. According to 2 large series, five
years survival in all stages ranged between 16 and 25%
[18,20]. In our institution we conducted a retrospective
study of 14 localised small cell carcinoma of the urinary
bladder. The disease free survival was equal to 5.7 months
and the overall survival was equal to 29.5 months. Two
years survival was equal to 56% [6]. The prognostic of
patients with stage IV disease is very poor. In the Mayo
Clinic study, 19 patients were diagnosed with stage IV dis-
ease (with or without distant metastasis), only 2 were sur-
vivors. The median overall survival for patients with stage
IV disease was 11 months and the one year survival rate
Overall survival in patients with pure neuroendocrine tumours of bladder vs tumours with mixed histology: The median dura- tion of overall survival was 9.9 months (n = 9, 7 events) in the mixed small cell carcinoma (SmCC) group, as compared with 4.6  months (n = 6, 5 events) in the pure SmCC group Figure 2
Overall survival in patients with pure neuroendocrine tumours of bladder vs tumours with mixed histology: 
The median duration of overall survival was 9.9 months (n = 9, 7 events) in the mixed small cell carcinoma 
(SmCC) group, as compared with 4.6 months (n = 6, 5 events) in the pure SmCC group. Survival probability at 1 
year in the mixed small cell carcinoma was 44% as compared with 17% in the pure small cell carcinoma group (Log-rank test: P 
= 0.228).BMC Urology 2009, 9:4 http://www.biomedcentral.com/1471-2490/9/4
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for theses patients was 36.8%. The results obtained in our
series were in concordance with previous Mayo Clinic
results and showed a 7.6-month median survival and 33%
survival probability at 1 year [18].
Treatment algorithms have been extrapolated from the
treatment of SCLC and often involved chemotherapy. The
gold standard chemotherapy for patients with good per-
formance status SCLC was platinum based regimen, typi-
cally cisplatin-etoposide [26-28]. In analogy to SCLC,
cisplatin-etoposide regimen was mostly used in the man-
agement of SCCB either in LS or ES [17,18,23]. In ES
SCLC, irinotecan-cisplatine regimen was shown to be an
effective treatment [29,30]. Other chemotherapy regi-
mens including etoposide-cisplatine alternating protocol
either with ifosfamide-doxorubicin or with cyclophos-
phamide, doxorubicin and vincristine (CAV), as well as
single agents, including paclitaxel, irinotecan, topotecan,
and doxorubicin, have all been used in SCCB [18,23]. The
MD Anderson group showed that preoperative chemo-
therapy with a neuroendocrine regimen was more likely
to successfully eradicate the small cell component com-
pared to regimens typically used for transitional cell carci-
noma. In fact, within the 12 patients treated with a
neuroendocrine regimen only 2 had small cell carcinoma
present at cystectomy. However, for those 9 patients
treated with a transitional cell carcinoma regimen (meth-
otrexate, vinmblastine, doxorubicin, and cisplatin: MVAC
regimen) 6 had small cell carcinoma still present at cystec-
tomy [23]. Consequently, this group recommend the pro-
tocols used in the neuroendocrine tumours containing
etoposide and cisplatin or ifosfamide and doxorubicin for
both histological types: pure small cell carcinoma and
mixed small cell carcinoma of the bladder. Other authors
recommended a regimen covering both small cell compo-
nent and transitional cell component for mixed SCCB: the
Table 5: Table summarizes chemotherapeutic regimen used in the management of SCCB
Regimen Schedule Drugs and doses
First line chemotherapy: Mixed and pure SCC
EP [18,21,22] On day 1 to 3, 
repeated after 21 
days
Etoposide 120 mg/
m2 on day 1 to 3
Cisplatin 80–100 
mg/m2, on day 1
IP [28,29] On day 1, 8, and 
15, repeated every 
28 days
Irinotecan 60 mg/
m2 on days 1, 8 
and 15
Cisplatin 60 mg/m2 
on day 1
VIP [21] On day 1 to 4, 
repeated after 21 
days
Ifosfamide 1.2 g/
m2, on day 1 to 4
Etoposide 75 mg/
m2 on day 1 to 4
Cisplatin 20 mg/m2 
on day 1 to 4
EP/CAV [22] Alternative 
regimen: PE on day 
1 to 3 repeated 
after 42 days and 
CAV on day 1 
repeated after 42 
days
Etoposide 100 mg/
m2 on day 1 to 3
Cisplatin 80 mg/
m2, on day 1
Cyclophosphamid
e 800 mg/m2
Doxorubicin 50 
mg/m2
Vincristine 1.4 mg/
m2
First line: mixed SCC
MVAC [18] On day 1, 2, 15, 
and 22, repeated 
after 28 days
Methotrexate 30 
mg/m2 on day 1, 15 
and 22
Vimblastine 3 mg/
m2 on day 2, 15, 
and 22
Doxorubicin 30 
mg/m2 on day 2
Cispatin 70 mg/m2 
on day 2
Second line chemotherapy in analogy to SCLC
IV Topotecan [18] On day 1 to 5, 
repeated every 21 
days
Topotecan 1.5 mg/
m2 on day 1 to 5
CAV On day 1, repeated 
every 21 days
Cyclophosphamide 
800 mg/m2
Doxorubicin 50 
mg/m2
Vincristine 1.4 mg/
m2
TP On day 1 to 5, 
repeated every 21 
days
Topotecan 0.75 
mg/m2 on day 1 to 
5
Cisplatin 60 mg/m2 
on day 1
EP = etoposide and cisplatin; VIP = etoposide, ifosfamide and cisplatin: PE/CAV = cisplatin and etoposide/cyclophosphamide, doxorubicin and 
vincristine; CEA = cyclophosphamide, etoposide and doxorubicin; CaE = carboplatin and etoposide; MVAC = methotrexate, vinmblastine, 
doxorubicin and cisplatin; IV = intravenous; SCC = small cell carcinoma; SCLC = small cell lung cancerBMC Urology 2009, 9:4 http://www.biomedcentral.com/1471-2490/9/4
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addition of taxane or ifosfamide to the standard platinum
plus etoposide regimen may be considered [24]. Table 5
summarizes the most used regimen in the management of
SCCB in analogy to SCLC. Similarly, four patients in our
series were successfully managed by chemotherapy using
etoposide plus cisplatin regimen with 28.3 months mean
survival. In addition, the patients treated with local treat-
ment (surgery and/or radiotherapy) plus chemotherapy
had the same mean survival as patients treated with chem-
otherapy alone (13.8 vs 14.7 months). These results sug-
gested that chemotherapy was more significant than local
treatments. In analogy to SCLC, radiotherapy can be used
to palliate brain metastases, symptomatic bone metas-
tases and cord compression [31]. One of our patients with
brain metastasis only, was managed with palliative whole
brain radiotherapy only, but the disease progressed and
the patient was dead 3.7 months later.
Considering the generally poor prognosis of SCCB, novel
therapeutic strategies are needed to improve outcomes of
patients. Targeted therapies are now established for sev-
eral diseases, but have not yet been investigated in SCCB.
C-KIT protein expression has been reported in 27% of
cases of SCCB suggesting the possibility to consider the
therapeutic use of STI-571, a small molecule inhibitor of
C-KIT kinase activity, in patients with c-kit positive
tumours [15]. However, STI-571 has been tried in treat-
ment of SCLC and found to be ineffective [32-34].
Finally, we found that pure small cell carcinoma tended to
have poorer outcome than mixed small cell carcinoma of
the bladder. The median duration of survival was 9.9
months in the mixed small cell carcinoma group, as com-
pared with 4.6 months in the pure small cell carcinoma
group, but the difference was not statistically significant
(Log rank test: p = 0.228) (Figure 2). In two series, mixed
histology tended to do better than pure neuroendocrine
tumour [6,19].
Conclusion
Small cell carcinoma of the bladder is an uncommon
tumour. Recurrent and metastatic disease was associated
with very poor prognosis. The pure small cell carcinoma
appeared to have poorer outcome than the mixed small
cell carcinoma of the bladder. In the absence of prospec-
tive studies, the best treatment of this disease cannot be
established with certainty. From our study and from the
literature, we conclude that platinum-based chemother-
apy is the mainstay treatment for recurrent and metastatic
disease.
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